<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548009" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548009/" /><meta name="ncbi_pagename" content="Low Molecular Weight Heparins - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Low Molecular Weight Heparins - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Low Molecular Weight Heparins" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/11/13" /><meta name="citation_pmid" content="31643341" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548009/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Low Molecular Weight Heparins" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/11/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548009/" /><meta name="description" content="The low molecular weight heparins enoxaparin, dalteparin and tinzaparin are purified fragments of natural heparins that have anticoagulant activity and are used to treat patients at high risk of venous thrombosis. The low molecular weight heparins are associated with serum enzyme elevations during therapy that are usually asymptomatic and resolve rapidly upon stopping; the low molecular weight heparins have not been implicated in cases of acute, clinically apparent, idiosyncratic liver injury." /><meta name="og:title" content="Low Molecular Weight Heparins" /><meta name="og:type" content="book" /><meta name="og:description" content="The low molecular weight heparins enoxaparin, dalteparin and tinzaparin are purified fragments of natural heparins that have anticoagulant activity and are used to treat patients at high risk of venous thrombosis. The low molecular weight heparins are associated with serum enzyme elevations during therapy that are usually asymptomatic and resolve rapidly upon stopping; the low molecular weight heparins have not been implicated in cases of acute, clinically apparent, idiosyncratic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548009/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/LMW-Heparins/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548009/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B3EB20466A74100000000065001D7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548009_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548009_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Lovastatin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Loxapine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548009_"><span class="title" itemprop="name">Low Molecular Weight Heparins</span></h1><p class="small">Last Update: <span itemprop="dateModified">November 13, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="LMW-Heparins.OVERVIEW"><h2 id="_LMW-Heparins_OVERVIEW_">OVERVIEW</h2><div id="LMW-Heparins.Introduction"><h3>Introduction</h3><p>The low molecular weight heparins enoxaparin, dalteparin and tinzaparin are purified fragments of natural heparins that have anticoagulant activity and are used to treat patients at high risk of venous thrombosis. The low molecular weight heparins are associated with serum enzyme elevations during therapy that are usually asymptomatic and resolve rapidly upon stopping; the low molecular weight heparins have not been implicated in cases of acute, clinically apparent, idiosyncratic liver injury.</p></div><div id="LMW-Heparins.Background"><h3>Background</h3><p>Low molecular weight heparins are prepared from natural heparins isolated from porcine intestine or bovine lung by controlled depolymerization of the large natural heparin molecule (which has varying molecular weights averaging ~15,000 daltons) into smaller fragments and subsequent fractionation to obtain homogenous heparin fragments with biological activity and molecular weight averaging 4,000-5,000 daltons (range, 2,000-9,000 daltons). The low molecular weight heparins have the advantage of more favorable pharmacokinetics and fewer side effects, which allow for once daily administration and outpatient use. The onset of anticoagulation may be slower with low molecular weight compared to standard heparin, but the degree of anticoagulation is easier to maintain and manage. The mechanism of action of low molecular weight heparins is similar to that of standard heparin and involves binding to antithrombin III and inhibition of activated coagulation factors including thrombin and Factor IX. Current indications include prevention of deep vein thromboses in high risk individuals (such as after surgery or during immobilization), prevention of ischemic complications in patients with unstable angina (in combination with aspirin), and active treatment of deep vein thrombosis with or without pulmonary embolism (in combination with warfarin). Common side effects of the low molecular weight heparins include dizziness, fatigue, headache, indigestion, nausea, bleeding, ecchymoses, rash and urticaria. The dose regimen of the low molecular weight heparins varies by product, concentration units (mg vs anti-Factor IX IU) and indication. The typical regimen of treatment is once daily for 7 to 14 days, but longer term treatment is sometimes used in high risk situations including during cancer chemotherapy where there is a high risk of venous thomboses.</p><p>Enoxaparin (ee nox' a par' in) was the first small molecular weight heparin (average 4,500 daltons) to be approved for use in the United States (1993) and is available in liquid solution in several forms (ampoules, syringes) generically and under the brand name Lovenox.</p><p>Dalteparin (dal' te par' in) (average 5,000 daltons) was approved in the United States in 1994 and is available in liquid solution in single or multidose vials under the brand name Fragmin.</p><p>Tinzaparin (tin" za par' in) (average 4,500-5,500 daltons) was approved for use in the United States in 2000 and has more restricted indications. Tinzaparin is available as solution for injection in multidose vials under the brand name Innohep.</p></div><div id="LMW-Heparins.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>The low molecular weight heparins have been associated with serum aminotransferase elevations in 4% to 13% of patients, but values greater than 5 times the upper limit of normal (ULN) are not common and occur mostly among patients receiving the highest doses. These elevations generally arise within 3 to 7 days of starting therapy and are usually mild, do not cause symptoms, and resolve rapidly once therapy is stopped. The enzyme elevations may improve with dose adjustment and sometimes resolve despite continuation of treatment using the same dosage. Recurrence of liver injury with restarting therapy is not invariable and the clinical implications of these abnormalities are not clear. The relative rates of serum enzyme elevations among the different low molecular weight heparins has not been clearly defined, but the abnormalities can occur with all of the currently available products, although perhaps at a lower rate than with standard heparin. Neither standard nor the low molecular weight heparins have been convincingly implicated in cases of acute, clinically apparent idiosyncratic liver injury with jaundice.</p><p>Likelihood score: E (although a frequent cause of asymptomatic serum enzyme elevations, the low molecular weight heparins are unlikely causes of clinically apparent liver injury).</p></div><div id="LMW-Heparins.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The low molecular weight heparins, like standard heparin, are likely to have a direct toxic effect on hepatocytes accounting for the frequency of serum enzyme elevations during therapy, particularly with higher doses. The mechanism of this injury is not known but has been reproduced in animal models.</p></div><div id="LMW-Heparins.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur during low molecular weight heparin therapy are usually self-limited and do not require dose modification or discontinuation of therapy. No convincing instances of clinically apparent or severe acute liver injury have been linked to the low molecular weight heparins in the published literature.</p><p>References to the safety and hepatotoxicity of the low molecular weight heparins are provided together at the end of the overview section on heparins.</p><p>Drug Class: <a href="/books/n/livertox/Anticoagulants/">Antithrombotic Agents</a>, <a href="/books/n/livertox/Anticoagulants/">Anticoagulants</a></p><p>Other Drugs in the Subclass: <a href="/books/n/livertox/Heparins/">Heparins</a>, <a href="/books/n/livertox/Heparin/">Heparin</a></p></div></div><div id="LMW-Heparins.CASE_REPORT_Low_Molecular_W"><h2 id="_LMW-Heparins_CASE_REPORT_Low_Molecular_W_">CASE REPORT</h2><div id="LMW-Heparins.Case_1._Asymptomatic_aminot"><h3>Case 1. Asymptomatic aminotransferase elevations during enoxaparin therapy.</h3><p>[Modified from: Hahn KJ, Morales SJ, Lewis JH. Enoxaparin-indued liver injury: case report and review of the literature and FDA Adverse Event Reporting System (FAERS). Drug Saf 2015: 2:17. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27747729" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>].</p><p>A 45 year old man with a dural venous thrombosis was anticoagulated starting with a heparin drip that was converted to a low molecular weight heparin, enoxaparin in a dose of 1 mg per kilogram subcutaneously twice daily. Before anticoagulation his liver tests were completely normal (Table). After 4 days of enoxaparin therapy serum aminotransferase levels were found to be elevated, although he had no symptoms of liver disease. He denied a history of liver disease, drug allergies, alcohol abuse and risk factors for viral hepatitis. His other medications were not provided. A physical examination was evidently unrevealing. Laboratory testing showed an <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 569 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 340 U/L, Alk P 89 U/L [R ratio=20], bilirubin 0.7 mg/dL [direct 0.1 mg/dL] and INR 1.1. Tests for hepatitis A, B and C and for EBV and CMV infection were negative as were routine autoantibodies. Abdominal ultrasound showed no evidence of biliary obstruction or other abnormalities. Enoxaparin was continued for several days, but ALT and AST levels continued to rise and the low molecular weight heparin was discontinued on day 7. Thereafter, serum enzymes elevations improved and they were near normal 2 weeks later. He was never jaundiced or symptomatic. He was later found to have adenocarcinoma of the colon which was considered a possible cause of a hypercoagulable state accounting for the dural venous thrombosis.</p><div id="LMW-Heparins.Key_Points"><h4>Key Points</h4><div id="LMW-Heparins.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548009/table/LMW-Heparins.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__LMW-Heparins.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Enoxaparin (1 mg/kg twice daily)</td></tr><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=20)</td></tr><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (enzyme elevations without jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4 days</td></tr><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Almost complete by 2 weeks</td></tr><tr><td rowspan="1" colspan="1" style="font-weight:bold;vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Not mentioned</td></tr></tbody></table></div></div></div><div id="LMW-Heparins.Laboratory_Values"><h4>Laboratory Values</h4><div id="LMW-Heparins.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548009/table/LMW-Heparins.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__LMW-Heparins.T2_lrgtbl__"><table><tbody><tr><th id="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days Since Starting</th><th id="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> <br />(mg/dL)</th><th id="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Pre</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">33</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">78</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.3</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Admission</td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">1</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Enoxaparin started</td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">5</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">579</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.7</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">6</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">644</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">104</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.5</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">7</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">770</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">103</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.4</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Enoxaparin stopped</td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">13</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">273</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">119</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.4</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Fondaparinux started</td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">22</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">70</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">97</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0.5</td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr><tr><td headers="hd_b_LMW-Heparins.T2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>Normal Values</b></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;41</b></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;126</b></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>&#x0003c;1.2</b></td><td headers="hd_b_LMW-Heparins.T2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></td></tr></tbody></table></div></div></div><div id="LMW-Heparins.Comment"><h4>Comment</h4><p>This patient was found to have elevations in serum aminotransferase levels, without symptoms, jaundice or other liver test abnormalities, 4 days after starting subcutaneous enoxaparin for treatment and prevention of venous thromboses. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> values continued to rise for the next two days, enoxaparin was stopped and the injury rapidly resolved. Liver injury did not recur upon switching therapy to fondaparinux, an oral anticoagulant that acts by inhibition of factor Xa. Typical of the liver injury that occurs in patients receiving low molecular weight heparins was the rapid onset (within 3 to 5 days of starting), rapid recover (generally within 1 to 4 weeks) and the absence of symptoms and jaundice. Some patients have mild increases in serum bilirubin and alkaline phosphatase, but they usually remain within the normal range. Indeed, without prospective monitoring, the injury may go undetected and resolve, even without discontinuation or dose modification. The injury seems to be partially dose related and the injury is not accumulative. The cause of the liver injury with heparins is unknown, but it resembles similar bouts of "transaminitis" due to high doses of penicillin (such as oxacillin) and bile acid resins (such as cholestyramine).</p></div></div></div><div id="LMW-Heparins.PRODUCT_INFORMATION_Daltepa"><h2 id="_LMW-Heparins_PRODUCT_INFORMATION_Daltepa_">PRODUCT INFORMATION</h2><div id="LMW-Heparins.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Dalteparin &#x02013; Fragmin&#x000ae;</p><p>Enoxaparin &#x02013; Generic, Lovenox&#x000ae;</p><p>Tinzaparin &#x02013; Innohep&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antithrombotic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Tinzaparin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="LMW-Heparins.CHEMICAL_FORMULAS_AND_STRUC"><h2 id="_LMW-Heparins_CHEMICAL_FORMULAS_AND_STRUC_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="LMW-Heparins.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548009/table/LMW-Heparins.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__LMW-Heparins.T3_lrgtbl__"><table><thead><tr><th id="hd_h_LMW-Heparins.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_LMW-Heparins.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_LMW-Heparins.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_LMW-Heparins.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_LMW-Heparins.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Dalteparin</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135346864" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">9005-49-6</a></td><td headers="hd_h_LMW-Heparins.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Unspecified</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">No Structure</td></tr><tr><td headers="hd_h_LMW-Heparins.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Enoxaparin</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135331472" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">679809-58-6</a></td><td headers="hd_h_LMW-Heparins.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Unspecified</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">No Structure</td></tr><tr><td headers="hd_h_LMW-Heparins.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Tinzaparin</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135346864" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">9005-49-6</a></td><td headers="hd_h_LMW-Heparins.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Unspecified</td><td headers="hd_h_LMW-Heparins.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">No Structure</td></tr></tbody></table></div></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548009</span><span class="label">PMID: <a href="/pubmed/31643341" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643341</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Lovastatin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Loxapine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548009&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548009/?report=reader">PubReader</a></li><li><a href="/books/NBK548009/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548009" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548009" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Low Molecular Weight Heparins. [Updated 2017 Nov 13].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548009/pdf/Bookshelf_NBK548009.pdf">PDF version of this page</a> (78K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Dalteparin/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/5/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Dalteparin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Dalteparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">: from ClinicalTrials.gov</a><a href="https://clinicaltrials.gov/ct2/results?term=Dalteparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Dalteparin: from ClinicalTrials.gov</a></li><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Enoxaparin/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/5/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Enoxaparin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Enoxaparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">: from ClinicalTrials.gov</a><a href="https://clinicaltrials.gov/ct2/results?term=Enoxaparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Enoxaparin: from ClinicalTrials.gov</a></li><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Tinzaparin/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/5/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Tinzaparin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Tinzaparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">: from ClinicalTrials.gov</a><a href="https://clinicaltrials.gov/ct2/results?term=Tinzaparin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Tinzaparin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4868220" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16286363" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Selecting an anticoagulant for recurrent venous thromboembolism in cancer.</a><span class="source">[Am J Health Syst Pharm. 2005]</span><div class="brieflinkpop offscreen_noflow">Selecting an anticoagulant for recurrent venous thromboembolism in cancer.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Goodin S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Health Syst Pharm. 2005 Nov 15; 62(22 Suppl 5):S10-3. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11776302" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.</a><span class="source">[Thromb Haemost. 2001]</span><div class="brieflinkpop offscreen_noflow">Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Thromb Haemost. 2001 Dec; 86(6):1374-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28857713" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.</a><span class="source">[J Oncol Pharm Pract. 2019]</span><div class="brieflinkpop offscreen_noflow">Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dranitsaris G, Shane LG, Woodruff S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Oncol Pharm Pract. 2019 Jan; 25(1):68-75. Epub 2017 Aug 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11401194" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.</a><span class="source">[Pharmacotherapy. 2001]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lopez LM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacotherapy. 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26684281" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.</a><span class="source">[Cochrane Database Syst Rev. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">van Zuuren EJ, Fedorowicz Z. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2015 Dec 18; (12):CD010155. Epub 2015 Dec 18.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643341" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643341" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604688dd4664552c12b449ea">Low Molecular Weight Heparins - LiverTox</a><div class="ralinkpop offscreen_noflow">Low Molecular Weight Heparins - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:28:13-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B3EB20466A74100000000065001D7&amp;ncbi_session=CE8B3EB204688DC1_1616SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548009%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548009&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548009/&amp;ncbi_pagename=Low Molecular Weight Heparins - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B3EB204688DC1_1616SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>